Chronic Lymphocytic Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Lymphocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-06-13Clinical Trial Update: A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia [Phase 1, Phase 2]
Clinical trial update for ABT-263 in relapsed or refractory chronic lymphocytic leukemia (Phase 1/Phase 2) completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-06-09Clinical Trial Update: High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant [Phase 2]
Phase 2 clinical trial evaluating high-dose cyclophosphamide, tacrolimus, and mycophenolate mofetil to prevent graft-versus-host disease in …
-
CLINICAL_TRIALS trial_result · 2023-06-07Clinical Trial Update: A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors [Phase 1, Phase 2]
Phase 1/2 clinical trial update for ASN002 in relapsed/refractory lymphoma and advanced solid tumors; the study status is TERMINATED with re…
-
CLINICAL_TRIALS trial_result · 2023-06-05Clinical Trial Update: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL [Phase 3]
A Phase 3 trial comparing ICP-022 to chlorambucil plus rituximab in untreated CLL/SLL is underway, with status currently unknown.
-
CLINICAL_TRIALS trial_result · 2023-05-22Clinical Trial Update: A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL. [Phase 1, Phase 2]
A safety, tolerability, pharmacokinetics and efficacy study of GB261 in B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia is in P…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-04-27Clinical Trial Update: Reduced Intensity Conditioning Transplant Using Haploidentical Donors [Phase 2]
Phase 2 clinical trial investigating reduced intensity conditioning transplant using haploidentical donors for various hematologic malignanc…
-
CLINICAL_TRIALS trial_result · 2023-04-19Clinical Trial Update: Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Phase 2]
A Phase 2 trial evaluating the combination of ibrutinib, fludarabine, and pembrolizumab in high-risk or relapsed/refractory chronic lymphocy…
-
CLINICAL_TRIALS trial_result · 2023-03-30Clinical Trial Update: Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic Leukemia [Phase 4]
Phase 4 clinical trial update evaluating immune response after pneumococcal vaccination in a patient with chronic lymphocytic leukemia.
-
CLINICAL_TRIALS trial_result · 2023-03-24Clinical Trial Update: TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL) [Phase 2]
Phase 2 trial evaluating umbralisib (TGR-1202) in treatment-naïve chronic lymphocytic leukemia was terminated; results were posted.
-
CLINICAL_TRIALS trial_result · 2023-03-23Clinical Trial Update: Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL) [Phase 2]
Phase II trial update of eltrombopag in chronic lymphocytic leukemia has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-03-21Clinical Trial Update: Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas [Phase 2]
Phase 2 trial of pembrolizumab alone or with idelalisib or ibrutinib in relapsed/refractory chronic lymphocytic leukemia or various low-grad…
-
CLINICAL_TRIALS trial_result · 2023-02-22Clinical Trial Update: A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent). [Phase 3]
Phase 3 trial evaluating venetoclax monotherapy in relapsed or refractory chronic lymphocytic leukemia; results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-02-21Clinical Trial Update: A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07 [Phase 3]
Phase 3 extension study in chronic lymphocytic leukemia/small lymphocytic lymphoma evaluating duvelisib with ofatumumab has completed enroll…
-
CLINICAL_TRIALS trial_result · 2023-01-31Clinical Trial Update: Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL [Phase 1, Phase 2]
Dose-escalation early-stage trial assessing safety of PBCAR20A in relapsed/refractory Non-Hodgkin's Lymphoma and relapsed/refractory Chronic…
-
CLINICAL_TRIALS trial_result · 2023-01-31Clinical Trial Update: Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention [Phase 3]
Phase 3 trial comparing Tacrolimus plus mini-methotrexate versus Tacrolimus plus methotrexate for graft-versus-host disease prevention has c…
-
CLINICAL_TRIALS trial_result · 2023-01-23Clinical Trial Update: Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis [Phase 2]
Phase 2 trial of adoptive immunotherapy in relapsed hematological malignancies with early GVHD prophylaxis has completed enrollment and post…
-
CLINICAL_TRIALS trial_result · 2023-01-20Clinical Trial Update: Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant [Phase 2]
Phase 2 trial evaluating ibrutinib in patients with refractory or relapsed lymphoma after donor stem cell transplant completed; results post…
-
CLINICAL_TRIALS trial_result · 2023-01-17Clinical Trial Update: Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL [Phase 2]
Phase 2 trial evaluating the combination of ibrutinib, venetoclax, and obinutuzumab in patients with chronic lymphocytic leukemia (CLL) has …
-
CLINICAL_TRIALS trial_result · 2023-01-10Clinical Trial Update: Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL [Phase 3]
Phase 3 trial evaluating acalabrutinib with obinutuzumab and chlorambucil for treatment-naïve chronic lymphocytic leukemia; results have bee…
-
CLINICAL_TRIALS trial_result · 2023-01-10Clinical Trial Update: Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL [Phase 3]
Phase 3 trial update on acalabrutinib with obinutuzumab and chlorambucil in treatment-naïve chronic lymphocytic leukemia.
-
CLINICAL_TRIALS trial_result · 2022-12-19Clinical Trial Update: A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy [Phase 2]
Phase 2 open-label study of ABT-199 (venetoclax) in chronic lymphocytic leukemia patients relapsed/refractory after BCR signaling pathway in…
-
CLINICAL_TRIALS trial_result · 2022-11-28Clinical Trial Update: iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL [Phase 2]
Phase 2 clinical trial update for iVAC-CLL01, a patient-individualized peptide vaccination after first-line therapy in chronic lymphocytic l…
-
CLINICAL_TRIALS trial_result · 2022-11-21Clinical Trial Update: Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Clinical trial update on ublituximab for relapsed or refractory B-cell non-Hodgkin lymphoma completed phases 1 and 2.
-
CLINICAL_TRIALS trial_result · 2022-11-03Clinical Trial Update: A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy [Phase 3]
A Phase 3 study in previously untreated chronic lymphocytic leukemia (excluding 17p deletion) evaluating debulking regimens before starting …
-
CLINICAL_TRIALS trial_result · 2022-11-03Clinical Trial Update: Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies [Phase 2]
Phase 2 clinical trial update on shorter course tacrolimus after non-myeloablative conditioning with related donor PBSCT and high-dose postt…